Grifols has Acquired 51% of the Capital of Araclon Biotech to Ensure the Viability of the Purchased Company Projects

20/03/2012
Fuente: MARKET WATCH, THE WALL STREET JOURNAL

Publicación: MARKET WATCH, THE WALL STREET JOURNAL